Pharmaceuticals December 7, 2023
Roche Enters Obesity Arena with Carmot Acquisition December 7, 2023
The already massive GLP-1 obesity drug segment might have gained a major future competitor last week, following Roche’s acquisition of weight loss biotech Carmot Therapeutics.
Cardiology December 4, 2023
Cardiac Wire Q&A: ECG Automation’s Care Impact December 4, 2023
In this Cardiac Wire Q&A, we sat down with AccurKardia CEO Juan C Jimenez and COO Mohamed Sadeq Ali to discuss ECG automation’s massive potential to improve clinical efficiency and care outcomes.
Surgeries & Interventions December 4, 2023
Medtronic and J&J’s LAA Expansions December 4, 2023
The left atrial appendage device space became far more competitive last week, following the launch of Medtronic’s Penditure LAA exclusion system and Johnson & Johnson MedTech’s acquisition of LAAX device company Laminar.
Cardiology November 30, 2023
The 35 Best Cardiology Newsletters, Websites, and Influencers to Follow November 30, 2023
In this story we’re highlighting the best cardiology newsletters, websites, blogs, and accounts to follow if you want to know what’s happening in cardiology and where it’s headed.
Pharmaceuticals November 27, 2023
Bayer Halts Asundexia Factor XI Trial Due to Inefficacy November 27, 2023
The Factor XI inhibitor movement hit a setback last week, after Bayer announced that it halted its OCEANIC-AF trial due to asundexian’s lack of efficacy.
Surgeries & Interventions November 20, 2023
Medtronic’s Symplicity Spyral RDN System Lands FDA Approval November 20, 2023
The brand new US renal denervation arena gained its second major competitor on Friday, with the FDA approval and immediate commercial launch of Medtronic’s Symplicity Spyral RDN system.
Cardiology November 16, 2023
Cardiac Wire’s Top Six Takeaways from AHA 2023 November 16, 2023
Cardiac Wire's AHA 2023 recap, PCI improves angina symptoms, and plenty of other cardiology news.
Pharmaceuticals November 13, 2023
Lilly’s Zepbound (aka tirzepatide) Lands FDA Approval for Weight Loss November 13, 2023
The US obesity management arena gained a major new competitor last week with the FDA approval of Eli Lilly’s Zepbound, giving obese and overweight patients in the US a second (on-label) option beyond Novo Nordisk’s Wegovy.
Surgeries & Interventions November 9, 2023
Recor Medical’s Paradise Renal Denervation System Lands FDA Approval November 9, 2023
The renal denervation race hit a major new milestone this week after Recor Medical’s Paradise system became the first to land FDA approval for hypertension.
Population Health November 6, 2023
America’s Cholesterol Awareness Problem November 6, 2023
The prevalence of US adults with high LDL cholesterol levels, and the prevalence of adults who are unaware of their high LDL-C are both declining. However, these improvements aren't happening nearly fast enough - especially given our expanding cholesterol treatment options.
Pharmaceuticals November 2, 2023
Chinese Medicine Tongxinluo Improves STEMI Outcomes, Sparks Debates November 2, 2023
Could the next major heart attack treatment come from a traditional Chinese medicine? A new JAMA study suggests that might be more realistic than many of us think, after showing that the Chinese medicine Tongxinluo significantly improves outcomes among patients with acute ST-segment elevation myocardial infarction (STEMI).
Surgeries & Interventions October 30, 2023
Promising Drug-Coated Balloon Results for In-Stent Restenosis October 30, 2023
The United States has been way behind other nations in using drug-coated balloons to treat coronary in-stent restenosis, but that might change soon thanks to the results from the AGENT IDE Trial.
Artificial Intelligence October 26, 2023
Healthcare AI Clearances Boom, While Cardiology AI Stalls October 26, 2023
The FDA’s annual Healthcare AI Report had medtech social media buzzing this week, showing that an impressive 692 AI-enabled devices have landed FDA clearance as of July 2023, while revealing an apparent slowdown in cardiovascular AI approvals.
Pharmaceuticals October 23, 2023
Pemvidutide’s Weight Loss and CVD Evidence October 23, 2023
Interim Phase 2 results from the MOMENTUM trial show that Altimmune’s pemvidutide drove significant weight loss and improved key cardiovascular metrics.
Pharmaceuticals October 19, 2023
Novo Nordisk Expands CV Pipeline with Ocedurenone Acquisition October 19, 2023
Novo Nordisk took advantage of its semaglutide windfall, expanding its cardiovascular drug pipeline by acquiring ocedurenone from KBP Biosciences for $1.3 billion.
Cardiology October 13, 2023
GE and Mediport’s One-Stop Cardiology Clinic October 13, 2023
With a direct target on streamlining the cardiovascular care pathway, GE HealthCare and Belgian healthcare organization Mediport announced the launch of the first One-Stop Clinic for Cardiology.
Pharmaceuticals October 12, 2023
Semaglutide Adds to Cardiovascular Resume October 12, 2023
Semaglutide continued to add to its cardiovascular resume, with two new studies highlighting its ability to improve heart failure symptoms and cardiorenal outcomes.
Value-Based Care October 9, 2023
CVAUSA and InnovaCare’s Value-Based Alliance October 9, 2023
A new Cardiovascular Associates of America and InnovaCare Health is aiming to create a new model for cardiology + primary care VBC delivery.
Cardiology October 5, 2023
MedAxiom on the State of Cardiovascular Providers October 5, 2023
MedAxiom just released its 11th annual Compensation and Production Report, revealing general stability in 2022 after years of significant change.